HK1143529A1 - Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor /(arb)(nep) - Google Patents
Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor /(arb)(nep)Info
- Publication number
- HK1143529A1 HK1143529A1 HK10109891.9A HK10109891A HK1143529A1 HK 1143529 A1 HK1143529 A1 HK 1143529A1 HK 10109891 A HK10109891 A HK 10109891A HK 1143529 A1 HK1143529 A1 HK 1143529A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- arb
- nep
- superstructures
- blocker
- inhibitor
- Prior art date
Links
- 102000003729 Neprilysin Human genes 0.000 title 1
- 108090000028 Neprilysin Proteins 0.000 title 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 title 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98566807P | 2007-11-06 | 2007-11-06 | |
PCT/US2008/082324 WO2009061713A1 (en) | 2007-11-06 | 2008-11-04 | Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1143529A1 true HK1143529A1 (en) | 2011-01-07 |
Family
ID=40451030
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11107642.4A HK1149721A1 (zh) | 2007-11-06 | 2010-10-19 | 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的雙向作用藥物組合物 |
HK10109891.9A HK1143529A1 (en) | 2007-11-06 | 2010-10-19 | Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor /(arb)(nep) |
HK16112495.7A HK1224195A1 (zh) | 2007-11-06 | 2016-10-31 | 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的藥物組合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11107642.4A HK1149721A1 (zh) | 2007-11-06 | 2010-10-19 | 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的雙向作用藥物組合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16112495.7A HK1224195A1 (zh) | 2007-11-06 | 2016-10-31 | 基於血管緊張素受體拮抗劑/阻斷劑 及中性內肽酶 抑制劑的超結構的藥物組合物 |
Country Status (34)
Country | Link |
---|---|
US (3) | US20100267786A1 (de) |
EP (4) | EP2295035B1 (de) |
JP (2) | JP5653218B2 (de) |
KR (2) | KR101589317B1 (de) |
CN (2) | CN101848700A (de) |
AR (1) | AR069184A1 (de) |
AU (1) | AU2008324878B2 (de) |
BR (1) | BRPI0823505A2 (de) |
CA (1) | CA2703598C (de) |
CL (1) | CL2008003298A1 (de) |
CY (2) | CY1116280T1 (de) |
DK (3) | DK2295035T3 (de) |
EC (1) | ECSP10010160A (de) |
ES (3) | ES2536514T3 (de) |
FI (1) | FI3067043T3 (de) |
GT (1) | GT201000131A (de) |
HK (3) | HK1149721A1 (de) |
HR (3) | HRP20230178T3 (de) |
HU (2) | HUE028866T2 (de) |
IL (3) | IL262990B2 (de) |
JO (1) | JOP20080499B1 (de) |
MA (1) | MA31797B1 (de) |
MX (1) | MX2010004930A (de) |
MY (1) | MY153730A (de) |
NZ (1) | NZ584686A (de) |
PE (2) | PE20141072A1 (de) |
PL (3) | PL2217205T3 (de) |
PT (3) | PT3067043T (de) |
RU (1) | RU2493844C3 (de) |
SG (1) | SG185951A1 (de) |
SI (3) | SI3067043T1 (de) |
TN (1) | TN2010000200A1 (de) |
TW (1) | TWI484982B (de) |
WO (1) | WO2009061713A1 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY153730A (en) | 2007-11-06 | 2015-03-13 | Novartis Ag | Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
EA019511B1 (ru) | 2009-05-28 | 2014-04-30 | Новартис Аг | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина |
MA33364B1 (fr) | 2009-05-28 | 2012-06-01 | Novartis Ag | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
EP2608784B1 (de) | 2010-08-24 | 2018-09-19 | Novartis AG | Behandlung und/oder prävention von herzinsuffizienz beim menschen mit einer antikoagulationstherapie |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
WO2014029848A1 (en) | 2012-08-24 | 2014-02-27 | Novartis Ag | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
SI2956464T1 (en) | 2013-02-14 | 2018-08-31 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (neutral endopeptidases) |
JP6301371B2 (ja) | 2013-02-14 | 2018-04-11 | ノバルティス アーゲー | インビボ効力が改善されたnep阻害剤としての置換ビスフェニルブタン酸誘導体 |
EP3038653A1 (de) * | 2013-08-26 | 2016-07-06 | Novartis AG | Neue verwendung |
DK3626270T3 (da) | 2013-08-26 | 2024-01-15 | Novartis Ag | Behandling af kardiovaskulære sygdomme |
WO2015154673A1 (en) * | 2014-04-10 | 2015-10-15 | Zhaoyin Wang | Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases |
CN105461647B (zh) * | 2014-09-28 | 2018-06-29 | 四川海思科制药有限公司 | 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途 |
HUE043014T2 (hu) | 2014-12-08 | 2019-07-29 | Crystal Pharmatech Co Ltd | Valzartánt és AHU 377-et tartalmazó trinátrium szupramolekuláris komplex kristályos formái, és az ezekhez tartozó eljárások |
CN104473938B (zh) * | 2014-12-30 | 2017-06-09 | 北京瑞都医药科技有限公司 | 一种治疗慢性心衰药物及其制备方法 |
CN104826115A (zh) * | 2015-04-19 | 2015-08-12 | 浙江巨泰药业有限公司 | 一种抗心衰药物组合物及其制备方法 |
US11058667B2 (en) | 2015-05-11 | 2021-07-13 | Novartis Ag | Sacubitril-valsartan dosage regimen for treating heart failure |
EP3302460A1 (de) | 2015-05-29 | 2018-04-11 | Novartis AG | Sacubitril und valsartan zur behandlung von stoffwechselkrankheiten |
CN106309388A (zh) * | 2015-06-30 | 2017-01-11 | 深圳信立泰药业股份有限公司 | 一种用于心衰治疗的药物组合物及其制备方法 |
WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
CN105997993B (zh) * | 2015-07-11 | 2018-03-30 | 麦丽芳 | 一种用于心血管疾病治疗的固体口服型制剂及其制备方法 |
CN105997994A (zh) * | 2015-07-11 | 2016-10-12 | 凌莉 | 一种固体口服型制剂及其制备方法 |
CN106074421A (zh) * | 2015-07-11 | 2016-11-09 | 凌莉 | 一种提高稳定性的药物组合物 |
CN106176725A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种提高稳定性的药物组合物及其制备方法和用途 |
CN106176724A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种稳定的固体药物组合物及其制备方法 |
CN106176723A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种固体药物组合物及其制备方法 |
WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
CN106389374A (zh) * | 2015-08-03 | 2017-02-15 | 深圳信立泰药业股份有限公司 | 一种含有lcz696的药物组合物及其制备方法 |
WO2017037596A1 (en) * | 2015-08-28 | 2017-03-09 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersion of lcz-696 |
EP3355880A1 (de) | 2015-08-28 | 2018-08-08 | Novartis AG | Neue verwendung |
US20180303799A1 (en) * | 2015-10-16 | 2018-10-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd | An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation Method |
CN105669581B (zh) * | 2015-11-09 | 2017-03-22 | 成都苑东生物制药股份有限公司 | 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物 |
WO2017085573A1 (en) * | 2015-11-20 | 2017-05-26 | Lupin Limited | Amorphous sacubitril-valsartan complex and process for preparation thereof |
CN105330609B (zh) * | 2015-12-07 | 2017-12-22 | 南京正大天晴制药有限公司 | 一种制备lcz696的方法 |
CN105929031B (zh) * | 2015-12-18 | 2018-08-21 | 重庆两江药物研发中心有限公司 | 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法 |
CN105935358B (zh) * | 2015-12-18 | 2019-06-07 | 重庆两江药物研发中心有限公司 | 一种沙库比曲缬沙坦缓释剂及其制备方法 |
CN106905253B (zh) * | 2015-12-23 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 一种超分子复合物的结晶 |
AU2017215530B2 (en) * | 2016-02-03 | 2019-09-12 | Novartis Ag | Galenic formulations of organic compounds |
US10722471B2 (en) * | 2016-02-03 | 2020-07-28 | Novartis Ag | Galenic formulations of organic compounds |
CN105748420B (zh) * | 2016-03-04 | 2018-11-06 | 山东省药学科学院 | 一种治疗心力衰竭的lcz696缓释骨架片的制备方法 |
CN105902506A (zh) * | 2016-06-12 | 2016-08-31 | 佛山市腾瑞医药科技有限公司 | 一种沙卡布曲缬沙坦制剂及其应用 |
WO2018069937A1 (en) | 2016-10-13 | 2018-04-19 | Mylan Laboratories Limited | Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof |
US20210085610A1 (en) * | 2017-03-31 | 2021-03-25 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Stable hot-melt extrudate containing valsartan and sacubitril |
WO2018178295A1 (en) | 2017-03-31 | 2018-10-04 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Stable hot-melt extrudate containing valsartan and sacubitril |
WO2018211479A1 (en) | 2017-05-19 | 2018-11-22 | Lupin Limited | Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof |
WO2019008485A1 (en) | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL |
EA202090398A1 (ru) | 2017-07-28 | 2020-05-15 | Синтон Б.В. | Фармацевтическая композиция, включающая сакубитрил и валсартан |
US20200276129A1 (en) | 2017-10-13 | 2020-09-03 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Tablet containing valsartan and sacubitril |
WO2019180735A1 (en) * | 2018-03-19 | 2019-09-26 | Natco Pharma Limited | Stable pharmaceutical compositions comprising sacubitril-valsartan complex |
US11877576B2 (en) | 2018-06-22 | 2024-01-23 | Ideaz, Llc | Diphenyl tablets and methods of preparing the same |
US20210177803A1 (en) | 2018-08-23 | 2021-06-17 | Novartis Ag | New pharmaceutical use for the treatment of heart failure |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
EP3766484B1 (de) | 2019-07-19 | 2021-08-25 | Zentiva, K.S. | Feste pharmazeutische darreichungsform mit valsartan und sakubitril |
KR102545274B1 (ko) | 2020-02-26 | 2023-06-20 | 에리슨제약(주) | 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법 |
KR20210120560A (ko) | 2020-03-27 | 2021-10-07 | 주식회사 유영제약 | 고함량의 주성분을 포함하는 정제 및 그 제조방법 |
KR20210138510A (ko) | 2020-05-12 | 2021-11-19 | 에리슨제약(주) | 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제 |
KR20220091767A (ko) | 2020-12-24 | 2022-07-01 | 주식회사 보령 | 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물 |
KR102486815B1 (ko) | 2021-01-20 | 2023-01-10 | 주식회사 대웅제약 | Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US608220A (en) | 1898-08-02 | Mechanical movement | ||
US607893A (en) | 1898-07-26 | Automatic switch-operating machine | ||
US607355A (en) | 1898-07-12 | Carrier for bicycles | ||
US735093A (en) | 1903-01-31 | 1903-08-04 | Oscar Greenwald | Elevator-cable guard. |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
JP4880118B2 (ja) * | 1997-11-17 | 2012-02-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 薬物高充填性の即時放出性または放出を修飾した経口用投与処方およびその製法 |
US6558699B2 (en) * | 1997-11-17 | 2003-05-06 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
AU750122C (en) * | 1998-06-17 | 2003-02-27 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination |
CZ293257B6 (cs) * | 1998-12-23 | 2004-03-17 | Novartis Ag | Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě |
HU229280B1 (en) | 2000-07-19 | 2013-10-28 | Novartis Ag | Valsartan salts |
AU2003206738C1 (en) * | 2002-01-17 | 2020-01-30 | Novartis Ag | Pharmaceutical compositions comprising valsartan and NEP inhibitors |
US7468390B2 (en) * | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
JP3751287B2 (ja) * | 2002-03-27 | 2006-03-01 | バイエル薬品株式会社 | 小型化されたニフェジピン有核錠剤 |
WO2003089417A1 (en) | 2002-04-15 | 2003-10-30 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan) |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
US20040242661A1 (en) | 2003-03-17 | 2004-12-02 | Igor Rukhman | Polymorphs of valsartan |
CA2532450C (en) | 2003-07-16 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
GB0402262D0 (en) * | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
US20090304755A1 (en) * | 2005-10-27 | 2009-12-10 | Raghu Rami Reddy Kasu | Pharmaceutical formulation of losartan |
US20080227836A1 (en) | 2005-10-31 | 2008-09-18 | Lupin Ltd | Stable Solid Oral Dosage Forms of Valsartan |
EP2260755B1 (de) | 2005-11-07 | 2013-12-25 | Stryker Corporation | Patientenhandhabungsvorrichtung mit normalzustandslampe |
CN101300030A (zh) | 2005-11-08 | 2008-11-05 | 诺瓦提斯公司 | 血管紧张素ⅱ受体阻滞剂、钙通道阻滞剂和另一活性物质的组合产品 |
AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
EP1897537A1 (de) * | 2006-09-04 | 2008-03-12 | Novartis AG | Zusammensetzung enthaltend einen Angiotensin II antagonisten |
MY153730A (en) | 2007-11-06 | 2015-03-13 | Novartis Ag | Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
-
2008
- 2008-11-04 MY MYPI2010001722A patent/MY153730A/en unknown
- 2008-11-04 PT PT161577671T patent/PT3067043T/pt unknown
- 2008-11-04 PL PL08848154T patent/PL2217205T3/pl unknown
- 2008-11-04 WO PCT/US2008/082324 patent/WO2009061713A1/en active Application Filing
- 2008-11-04 CN CN200880114940A patent/CN101848700A/zh active Pending
- 2008-11-04 HU HUE10173506A patent/HUE028866T2/en unknown
- 2008-11-04 PT PT88481544T patent/PT2217205E/pt unknown
- 2008-11-04 EP EP10173506.6A patent/EP2295035B1/de not_active Revoked
- 2008-11-04 ES ES08848154.4T patent/ES2536514T3/es active Active
- 2008-11-04 CA CA2703598A patent/CA2703598C/en active Active
- 2008-11-04 DK DK10173506.6T patent/DK2295035T3/en active
- 2008-11-04 FI FIEP16157767.1T patent/FI3067043T3/fi active
- 2008-11-04 EP EP16157767.1A patent/EP3067043B1/de active Active
- 2008-11-04 PL PL10173506.6T patent/PL2295035T3/pl unknown
- 2008-11-04 PL PL16157767.1T patent/PL3067043T3/pl unknown
- 2008-11-04 PT PT101735066T patent/PT2295035T/pt unknown
- 2008-11-04 SI SI200832204T patent/SI3067043T1/sl unknown
- 2008-11-04 MX MX2010004930A patent/MX2010004930A/es active IP Right Grant
- 2008-11-04 HU HUE16157767A patent/HUE061321T2/hu unknown
- 2008-11-04 DK DK08848154.4T patent/DK2217205T3/en active
- 2008-11-04 ES ES16157767T patent/ES2939163T3/es active Active
- 2008-11-04 EP EP22200982.1A patent/EP4186491A1/de active Pending
- 2008-11-04 CN CN2013101540642A patent/CN103251587A/zh active Pending
- 2008-11-04 BR BRPI0823505-8A patent/BRPI0823505A2/pt not_active Application Discontinuation
- 2008-11-04 KR KR1020107009852A patent/KR101589317B1/ko active IP Right Review Request
- 2008-11-04 EP EP08848154.4A patent/EP2217205B1/de not_active Revoked
- 2008-11-04 NZ NZ584686A patent/NZ584686A/xx unknown
- 2008-11-04 JP JP2010533185A patent/JP5653218B2/ja active Active
- 2008-11-04 US US12/741,251 patent/US20100267786A1/en not_active Abandoned
- 2008-11-04 DK DK16157767.1T patent/DK3067043T3/da active
- 2008-11-04 KR KR1020157033633A patent/KR101700062B1/ko active IP Right Review Request
- 2008-11-04 PE PE2013002393A patent/PE20141072A1/es active IP Right Grant
- 2008-11-04 SI SI200831427T patent/SI2217205T1/sl unknown
- 2008-11-04 AU AU2008324878A patent/AU2008324878B2/en active Active
- 2008-11-04 JO JOP/2008/0499A patent/JOP20080499B1/ar active
- 2008-11-04 RU RU2010123027A patent/RU2493844C3/ru active
- 2008-11-04 IL IL262990A patent/IL262990B2/en unknown
- 2008-11-04 PE PE2008001886A patent/PE20091390A1/es not_active Application Discontinuation
- 2008-11-04 ES ES10173506.6T patent/ES2587336T3/es active Active
- 2008-11-04 AR ARP080104826A patent/AR069184A1/es not_active Application Discontinuation
- 2008-11-04 SI SI200831654A patent/SI2295035T1/sl unknown
- 2008-11-04 SG SG2012081394A patent/SG185951A1/en unknown
- 2008-11-04 HR HRP20230178TT patent/HRP20230178T3/hr unknown
- 2008-11-05 CL CL2008003298A patent/CL2008003298A1/es unknown
- 2008-11-05 TW TW097142724A patent/TWI484982B/zh active
-
2010
- 2010-04-19 IL IL205208A patent/IL205208A/en active IP Right Grant
- 2010-04-30 TN TN2010000200A patent/TN2010000200A1/fr unknown
- 2010-04-30 MA MA32803A patent/MA31797B1/fr unknown
- 2010-05-05 GT GT201000131A patent/GT201000131A/es unknown
- 2010-05-06 EC EC2010010160A patent/ECSP10010160A/es unknown
- 2010-10-19 HK HK11107642.4A patent/HK1149721A1/zh not_active IP Right Cessation
- 2010-10-19 HK HK10109891.9A patent/HK1143529A1/xx not_active IP Right Cessation
-
2014
- 2014-08-12 JP JP2014164022A patent/JP2015038069A/ja not_active Withdrawn
-
2015
- 2015-04-28 HR HRP20150459TT patent/HRP20150459T1/hr unknown
- 2015-05-14 CY CY20151100426T patent/CY1116280T1/el unknown
-
2016
- 2016-08-02 HR HRP20160988TT patent/HRP20160988T1/hr unknown
- 2016-08-08 CY CY20161100778T patent/CY1117883T1/el unknown
- 2016-10-31 HK HK16112495.7A patent/HK1224195A1/zh unknown
-
2017
- 2017-01-03 IL IL249922A patent/IL249922A0/en unknown
-
2020
- 2020-12-02 US US17/109,716 patent/US20210085631A1/en not_active Abandoned
-
2023
- 2023-05-09 US US18/314,745 patent/US20240115536A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL262990A (en) | Dual-activity pharmaceutical compositions based on angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor superstructures | |
HUS2100003I1 (hu) | Angiotenzin receptor antagonista és NEP inhibitor gyógyszerészeti kombinációja | |
IL197788A0 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
PL2046887T3 (pl) | Kompozycje poliolefinowe ulegające sieciowaniu pod wpływem światła | |
IL192613A (en) | Cycloalkylamines and their pharmaceutical compositions | |
SI2059246T1 (sl) | Terapevtski sestavki, ki vsebujejo specifiäśne antagoniste za endotelin receptorje in inhibitor za pde5 | |
HK1135110A1 (en) | Nk1 receptor antagonist composition nk1 | |
EP2155160A4 (de) | Thixotrope pharmazeutische zusammensetzungen | |
ITMI20062230A1 (it) | Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende | |
ZA200704717B (en) | Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor | |
GB0619891D0 (en) | Pharmaceutical composition of risedronate | |
ZA200901001B (en) | Antiretroviral solid oral composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20201031 |